BRAF and non-small cell lung carcinoma: In a phase II study involving patients with advanced NSCLC harboring BRAF V600E mutation and PS less than two, the combination of dabrafenib and trametinib demonstrated an overall response rate of 64% in patients receiving first-line treatment.